3D Signatures Collaborates with mdxhealth to Evaluate Telo-PC(TM) Test in Prostate Cancer

3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the “Company” or “3DS“), a personalized medicine company with a proprietary software platform (TeloView^TM) based on the three-dimensional analysis of chromosomal signatures, is pleased to announce that it has signed a collaboration agreement with MDxHealth SA (Euronext: Brussels MDXH.BR) (“MDxHealth”), a world leader in molecular diagnostics for urological cancers, to evaluate 3DS’ prognostic test candidate for prostate cancer (“Telo-PC^TM“), using 3DS’ proprietary TeloView(TM) software platform.

3DS and MDxHealth will share the costs of conducting the collaborative study. Pursuant to the agreement, 3DS has also granted MDxHealth an exclusive option to negotiate a license agreement for the Telo-PC^TM test.

“This is an excellent opportunity, combining our expertise in urological diagnostics with the innovative 3DS software platform, to evaluate an exciting technology that may improve the clinical management of patients with prostate cancer,” said Dr. Jan Groen, CEO of MDxHealth. “MDxHealth is constantly evaluating new opportunities that might allow us to increase our commercial footprint and we look forward to collaborating with 3DS to explore the potential of this partnership.”

There is a significant unmet need for accurate and minimally invasive diagnostic and risk-assessment tools that allow clinicians to make more informed treatment decisions for prostate cancer patients. Traditionally, the diagnosis of prostate cancer has involved repeated invasive tissue biopsies, which can easily miss cancerous cells or misinterpret benign conditions as being dangerous, leading to unnecessary surgeries. This system needs urgent improvement as seen by the sheer number of people across the world affected by prostate cancer. According to the World Health Organization¹, there were over 570,000 new cases of prostate cancer in the U.S. and Europe in 2012. The U.S. National Institutes of Health² estimates there were over 3 million men living with prostate cancer in the United States in 2014. Currently, prostate cancer patients are often faced with the difficult choice of either living with cancer under active surveillance or pursuing treatment which has a significant risk of devastating side effects such as erectile dysfunction, incontinence, bowel complications and infection.

“We look forward to expanding the evaluation of our TeloView^TM platform in prostate cancer through a collaboration with MDxHealth, as they are recognized world leaders in molecular diagnostic testing for patients with prostate cancer,” commented Jason Flowerday, CEO of 3DS. “We hope this study will continue to build on the evidence observed to date which indicates that our Telo-PC^TM test is able to predict the stability and aggressiveness of prostate cancer through three-dimensional nuclear telomeric profile analysis.”

3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the “Company” or “3DS“), a personalized medicine company with a proprietary software platform (TeloView^TM) based on the three-dimensional analysis of chromosomal signatures, is pleased to announce that it has signed a collaboration agreement with MDxHealth SA (Euronext: Brussels MDXH.BR) (“MDxHealth”), a world leader in molecular diagnostics for urological cancers, to evaluate 3DS’ prognostic test candidate for prostate cancer (“Telo-PC^TM“), using 3DS’ proprietary TeloView(TM) software platform.

3DS and MDxHealth will share the costs of conducting the collaborative study. Pursuant to the agreement, 3DS has also granted MDxHealth an exclusive option to negotiate a license agreement for the Telo-PC^TM test.

“This is an excellent opportunity, combining our expertise in urological diagnostics with the innovative 3DS software platform, to evaluate an exciting technology that may improve the clinical management of patients with prostate cancer,” said Dr. Jan Groen, CEO of MDxHealth. “MDxHealth is constantly evaluating new opportunities that might allow us to increase our commercial footprint and we look forward to collaborating with 3DS to explore the potential of this partnership.”

There is a significant unmet need for accurate and minimally invasive diagnostic and risk-assessment tools that allow clinicians to make more informed treatment decisions for prostate cancer patients. Traditionally, the diagnosis of prostate cancer has involved repeated invasive tissue biopsies, which can easily miss cancerous cells or misinterpret benign conditions as being dangerous, leading to unnecessary surgeries. This system needs urgent improvement as seen by the sheer number of people across the world affected by prostate cancer. According to the World Health Organization¹, there were over 570,000 new cases of prostate cancer in the U.S. and Europe in 2012. The U.S. National Institutes of Health² estimates there were over 3 million men living with prostate cancer in the United States in 2014. Currently, prostate cancer patients are often faced with the difficult choice of either living with cancer under active surveillance or pursuing treatment which has a significant risk of devastating side effects such as erectile dysfunction, incontinence, bowel complications and infection.

“We look forward to expanding the evaluation of our TeloView^TM platform in prostate cancer through a collaboration with MDxHealth, as they are recognized world leaders in molecular diagnostic testing for patients with prostate cancer,” commented Jason Flowerday, CEO of 3DS. “We hope this study will continue to build on the evidence observed to date which indicates that our Telo-PC^TM test is able to predict the stability and aggressiveness of prostate cancer through three-dimensional nuclear telomeric profile analysis.”